Glioblastoma Immunotherapy
Glioblastoma Immunotherapy - Related Videos
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
0 Views •
Cited by 1 •
2023
The present protocol describes the purification steps and subsequent studies of four different fungal β-glucans as potential immunomodulatory molecules that enhance the anti-tumoral properties of microglia against glioblastoma cells.
01:27
Tumor Immunotherapy
0 Views •
2024
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:36
Generating a Glioblastoma Rat Model
0 Views •
2025
Source: Bolcaen, J., et. al., PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator. J. Vis. Exp. (2017)This video demonstrates the procedure for establishing a glioblastoma rat model by stereotactically injecting brain tumor-causing glioblastoma cells into the prefrontal cortex.
08:06
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
0 Views •
Cited by 21 •
2010
An experimental lung metastasis and CTL immunotherapy mouse model for analysis of tumor cells-T cell interaction in vivo.
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
0 Views •
Cited by 17 •
2015
The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.
FAQs
Glioblastoma immunotherapy must contend with tumor heterogeneity and local immunosuppression. Heterogeneity means that tumor cells may not share the same recognizable features, while immunosuppression can weaken immune activity within the tumor. Together, these conditions may allow resistant cell populations to persist, making a single immune strategy less effective and supporting investigation of personalized approaches.
These strategies differ in what they modify or deliver. Checkpoint inhibitors target immune regulation, therapeutic vaccines focus on immune recognition, chimeric antigen receptor T cells provide modified immune cells, and oncolytic viruses add a virus-based strategy. Comparing these categories helps investigators determine which immune intervention best addresses a tumor’s biology.
Access to the brain is a central design issue for glioblastoma immunotherapy. An approach may be promising in principle yet limited if immune cells cannot reach the tumor effectively. For this reason, researchers consider both immune activation and the ability of immune cells to enter the brain tumor when developing strategies for neuro-oncology.
Combination studies examine whether different treatments can address separate obstacles to tumor control. Researchers evaluate immune strategies alone and alongside surgery, radiation, chemotherapy, or targeted treatments. This approach is especially relevant when glioblastoma contains diverse cell populations or suppresses local immunity, because one intervention may not adequately address all of the tumor’s biological features.
Researchers evaluate glioblastoma immunotherapy both as a standalone treatment and alongside surgery, radiation, chemotherapy, or targeted treatments. This comparative design examines whether an immune strategy contributes to controlling tumor growth or extending survival within a broader treatment plan. It also places immune effects in the context of established and targeted neuro-oncology interventions.
Within neuroscience, the tumor microenvironment connects immune treatment to the biology of the brain tumor itself. Researchers examine how local immunosuppression and cellular diversity shape immune activity and treatment response. This context supports neuro-oncology strategies tailored to the tumor’s features rather than assuming that every glioblastoma will respond identically.
Researchers use control of tumor growth and extension of survival as central goals when studying these therapies. However, an approach must also be considered in relation to tumor heterogeneity, immune suppression, and access to the brain. These factors help explain why promising immune strategies may require combinations or more personalized selection.